Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term behavioral symptom clusters among survivors of early-stage breast cancer. development and validation of a predictive model.
Pagliuca M, Havas J, Thomas E, Drouet Y, Soldato D, Franzoi MA, Ribeiro J, Chiodi CK, Gillanders E, Pistilli B, Menvielle G, Joly F, Lerebours F, Rigal O, Petit T, Giacchetti S, Dalenc F, Wassermann J, Arsene O, Martin AL, Everhard S, Tredan O, Boyault S, De Laurentiis M, Viari A, Deleuze JF, Bertaut A, André F, Vaz-Luis I, Di Meglio A. Pagliuca M, et al. Among authors: tredan o. J Natl Cancer Inst. 2024 Sep 9:djae222. doi: 10.1093/jnci/djae222. Online ahead of print. J Natl Cancer Inst. 2024. PMID: 39250750
Role of PRMT1 and PRMT5 in Breast Cancer.
Martinez S, Sentis S, Poulard C, Trédan O, Le Romancer M. Martinez S, et al. Among authors: tredan o. Int J Mol Sci. 2024 Aug 14;25(16):8854. doi: 10.3390/ijms25168854. Int J Mol Sci. 2024. PMID: 39201539 Free PMC article. Review.
TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer.
Kabirian R, Tredan O, Marmé F, Paoletti X, Eberst L, Lebreton C, De La Motte Rouge T, Sabatier R, Angelergues A, Fabbro M, Van Gorp T, Mansi L, Gladieff L, Kaczmarek E, Alexandre J, Grellety T, Favier L, Welz J, Frenel JS, Leary A. Kabirian R, et al. Among authors: tredan o. Future Oncol. 2024;20(35):2699-2708. doi: 10.1080/14796694.2024.2386922. Epub 2024 Aug 19. Future Oncol. 2024. PMID: 39155847 Free PMC article. Clinical Trial.
Metabolomic Prediction of Breast Cancer Treatment-Induced Neurologic and Metabolic Toxicities.
Piffoux M, Jacquemin J, Pétéra M, Durand S, Abila A, Centeno D, Joly C, Lyan B, Martin AL, Everhard S, Boyault S, Pistilli B, Fournier M, Rouanet P, Havas J, Sauterey B, Campone M, Tarpin C, Mouret-Reynier MA, Rigal O, Petit T, Lasset C, Bertaut A, Cottu P, André F, Vaz-Luis I, Pujos-Guillot E, Drouet Y, Trédan O. Piffoux M, et al. Among authors: tredan o. Clin Cancer Res. 2024 Oct 15;30(20):4654-4666. doi: 10.1158/1078-0432.CCR-24-0195. Clin Cancer Res. 2024. PMID: 39106085
A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance 2 years later.
Di Meglio A, Havas J, Pagliuca M, Franzoi MA, Soldato D, Chiodi CK, Gillanders E, Dubuisson F, Camara-Clayette V, Pistilli B, Ribeiro J, Joly F, Cottu PH, Tredan O, Bertaut A, Ganz PA, Bower J, Partridge AH, Martin AL, Everhard S, Boyault S, Brutin S, André F, Michiels S, Pradon C, Vaz-Luis I. Di Meglio A, et al. Among authors: tredan o. Ann Oncol. 2024 Nov;35(11):1048-1060. doi: 10.1016/j.annonc.2024.07.728. Epub 2024 Aug 2. Ann Oncol. 2024. PMID: 39098454 Free article.
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial.
Ray-Coquard IL, Savoye AM, Schiffler C, Mouret-Reynier MA, Derbel O, Kalbacher E, LeHeurteur M, Martinez A, Cornila C, Martinez M, Bengrine Lefevre L, Priou F, Cloarec N, Venat L, Selle F, Berton D, Collard O, Coquan E, Le Saux O, Treilleux I, Gouerant S, Angelergues A, Joly F, Tredan O. Ray-Coquard IL, et al. Among authors: tredan o. Nat Commun. 2024 Jul 16;15(1):5931. doi: 10.1038/s41467-024-46999-x. Nat Commun. 2024. PMID: 39013870 Free PMC article. Clinical Trial.
Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer.
Poumeaud F, Morisseau M, Cabel L, Gonçalves A, Rivier C, Trédan O, Volant E, Frenel JS, Ladoire S, Jacot W, Jamelot M, Foka Tichoue H, Patsouris A, Teixeira L, Bidard FC, Loirat D, Brunet M, Levy C, Bailleux C, Cabarrou B, Deleuze A, Uwer L, Deluche E, Grellety T, Franchet C, Fiteni F, Bischoff H, Vion R, Pagliuca M, Verret B, Bécourt S, Reverdy T, de Nonneville A, Dalenc F. Poumeaud F, et al. Among authors: tredan o. Br J Cancer. 2024 Sep;131(4):702-708. doi: 10.1038/s41416-024-02766-9. Epub 2024 Jun 25. Br J Cancer. 2024. PMID: 38918555
Dose/Exposure Relationship of Exercise and Distant Recurrence in Primary Breast Cancer.
Soldato D, Michiels S, Havas J, Di Meglio A, Pagliuca M, Franzoi MA, Pistilli B, Iyengar NM, Cottu P, Lerebours F, Coutant C, Bertaut A, Tredan O, Vanlemmens L, Jouannaud C, Hrab I, Everhard S, Martin AL, André F, Vaz-Luis I, Jones LW. Soldato D, et al. Among authors: tredan o. J Clin Oncol. 2024 Sep 1;42(25):3022-3032. doi: 10.1200/JCO.23.01959. Epub 2024 Jun 5. J Clin Oncol. 2024. PMID: 38838281 Free PMC article.
Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Freyer G, Floquet A, Tredan O, Carrot A, Langlois-Jacques C, Lopez J, Selle F, Abdeddaim C, Leary A, Dubot-Poitelon C, Fabbro M, Gladieff L, Lamuraglia M. Freyer G, et al. Among authors: tredan o. Nat Commun. 2024 Jun 4;15(1):4753. doi: 10.1038/s41467-024-48915-9. Nat Commun. 2024. PMID: 38834579 Free PMC article. No abstract available.
219 results